Abstract
Treatment of serious P. aeruginosa infections becomes more challenging with each passing year. As this pathogen acquires more transferrable resistance mechanisms and continues to rapidly adapt and emerge resistant during the course of antimicrobial therapy, we face the growing threat of pan-resistance. This review has focused on those mechanisms that directly impact the future of β-lactam antibiotics, including the production of β-lactamases, porin-mediated resistance, and/or the overexpression of RND efflux pumps. With the pipeline of new anti-pseudomonal agents diminishing, it is essential that novel therapeutic strategies be explored. These include targeting biofilm formation and maintenance, virulence factors, and resistance mechanisms. Furthermore, we must continue to search for effective antibacterial combinations to not only prevent further emergence of resistance but also treat resistant strains already in the environment.
Keywords: Pseudomonas aeruginosa, β-lactam, resistance
Current Pharmaceutical Design
Title:Mechanisms of β -lactam Resistance Among Pseudomonas aeruginosa
Volume: 19 Issue: 2
Author(s): Daniel J. Wolter and Philip D. Lister
Affiliation:
Keywords: Pseudomonas aeruginosa, β-lactam, resistance
Abstract: Treatment of serious P. aeruginosa infections becomes more challenging with each passing year. As this pathogen acquires more transferrable resistance mechanisms and continues to rapidly adapt and emerge resistant during the course of antimicrobial therapy, we face the growing threat of pan-resistance. This review has focused on those mechanisms that directly impact the future of β-lactam antibiotics, including the production of β-lactamases, porin-mediated resistance, and/or the overexpression of RND efflux pumps. With the pipeline of new anti-pseudomonal agents diminishing, it is essential that novel therapeutic strategies be explored. These include targeting biofilm formation and maintenance, virulence factors, and resistance mechanisms. Furthermore, we must continue to search for effective antibacterial combinations to not only prevent further emergence of resistance but also treat resistant strains already in the environment.
Export Options
About this article
Cite this article as:
J. Wolter Daniel and D. Lister Philip, Mechanisms of β -lactam Resistance Among Pseudomonas aeruginosa, Current Pharmaceutical Design 2013; 19 (2) . https://dx.doi.org/10.2174/1381612811306020209
DOI https://dx.doi.org/10.2174/1381612811306020209 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Infection and Inflammation Targeting Compounds
Current Radiopharmaceuticals β-Lactams in the New Millennium. Part-II: Cephems, Oxacephems, Penams and Sulbactam
Mini-Reviews in Medicinal Chemistry Biofilms in Skin Infections: Propionibacterium acnes and Acne Vulgaris
Infectious Disorders - Drug Targets Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis
Current Clinical Pharmacology Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach
Current Drug Targets Radiolabelled Probes Targeting Infection and Inflammation for Personalized Medicine
Current Pharmaceutical Design A New Binding Site Involving the C-terminal Domain to Design Specific Inhibitors of PepX
Protein & Peptide Letters Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Stability Assessment of Extemporaneous Formulation of Amoxicillin for Parenteral Antimicrobial Therapy
Current Pharmaceutical Analysis Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus
Current Pharmaceutical Biotechnology Models of In-Vivo Bacterial Infections for the Development of Antimicrobial Peptide-based Drugs
Current Topics in Medicinal Chemistry Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology DNA Microarrays - An Armory for Combating Infectious Diseases in the New Century
Infectious Disorders - Drug Targets Gut Microbiota of Obese, Type 2 Diabetic Individuals is Enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after Weight Loss
Endocrine, Metabolic & Immune Disorders - Drug Targets Methylene Blue not Contraindicated in Treating Hemodynamic Instability in Pediatric and Neonate Patients
Current Pediatric Reviews Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Bacterial Adaptation and Infection
Inflammation & Allergy - Drug Targets (Discontinued) Antimicrobial Peptides and Peptidomimetics - Potent Therapeutic Allies for Staphylococcal Infections
Current Pharmaceutical Design Discovery of Medically Significant Lantibiotics
Current Drug Discovery Technologies